Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
anemia
Biotech
Incyte scraps cancer-related anemia program after ph. 1/2 fail
Incyte is dropping a cancer-related anemia program after its investigational small molecule failed to improve symptoms in a phase 1/2 trial.
Darren Incorvaia
Dec 13, 2024 2:30pm
Takeda pays Keros $200M upfront for rival to BMS' Reblozyl
Dec 3, 2024 7:30am
Agios' next-up PK med quelled transfusion need in some patients
Nov 20, 2023 11:24am
FDA delays approval decision on GSK's $1.9B blood cancer bet
Jun 16, 2023 6:50am
Rocket's hematology programs blast off toward regulators
May 19, 2023 11:01am
FibroGen snags sole ADC asset from small biotech for $280M
May 9, 2023 1:20pm
